| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
|
Lancet Oncol
|
2012
|
3.75
|
|
2
|
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
|
Lancet Oncol
|
2007
|
3.51
|
|
3
|
FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.
|
Head Neck
|
2002
|
1.66
|
|
4
|
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
|
Clin Genitourin Cancer
|
2012
|
1.28
|
|
5
|
177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
|
Cancer
|
2010
|
1.27
|
|
6
|
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
|
Eur J Nucl Med Mol Imaging
|
2011
|
1.13
|
|
7
|
Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
|
Clin Cancer Res
|
2004
|
1.06
|
|
8
|
90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy.
|
J Nucl Med
|
2010
|
1.03
|
|
9
|
Tumour therapy with radionuclides: assessment of progress and problems.
|
Radiother Oncol
|
2003
|
1.02
|
|
10
|
Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients.
|
Clin Cancer Res
|
2003
|
1.01
|
|
11
|
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
|
Clin Cancer Res
|
2005
|
0.94
|
|
12
|
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
|
Cancer Biother Radiopharm
|
2005
|
0.94
|
|
13
|
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
|
Biol Blood Marrow Transplant
|
2009
|
0.87
|
|
14
|
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
|
Cancer
|
2002
|
0.87
|
|
15
|
Clinical applications of newer radionuclide therapies.
|
Eur J Cancer
|
2006
|
0.87
|
|
16
|
Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
|
Cancer Biother Radiopharm
|
2012
|
0.85
|
|
17
|
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden.
|
Acta Oncol
|
2002
|
0.81
|
|
18
|
Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
|
Cancer Biother Radiopharm
|
2012
|
0.80
|
|
19
|
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy.
|
Clin Cancer Res
|
2007
|
0.80
|
|
20
|
High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
|
Cancer
|
2010
|
0.80
|
|
21
|
Consequences of inadvertent radioiodine treatment of Graves' disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing?
|
Acta Oncol
|
2008
|
0.80
|
|
22
|
Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
|
Med Phys
|
2012
|
0.79
|
|
23
|
Change in cell death markers during (177)Lu-mAb radioimmunotherapy-induced rejection of syngeneic rat colon carcinoma.
|
Cancer Biother Radiopharm
|
2014
|
0.78
|
|
24
|
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
|
Clin Cancer Res
|
2005
|
0.77
|
|
25
|
Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
|
Artif Organs
|
2007
|
0.77
|
|
26
|
Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
|
Cancer Biother Radiopharm
|
2014
|
0.77
|
|
27
|
Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer.
|
Anticancer Res
|
2005
|
0.77
|
|
28
|
The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
|
J Nucl Med
|
2013
|
0.76
|
|
29
|
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
|
J Nucl Med
|
2007
|
0.76
|
|
30
|
Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
|
Acta Oncol
|
2005
|
0.76
|
|
31
|
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
|
Acta Oncol
|
2002
|
0.75
|
|
32
|
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
|
EJNMMI Res
|
2013
|
0.75
|
|
33
|
Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
|
Acta Oncol
|
2011
|
0.75
|
|
34
|
Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
|
Cancer Biother Radiopharm
|
2003
|
0.75
|
|
35
|
Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
|
Cytometry A
|
2007
|
0.75
|
|
36
|
[Quality shortages in the diagnostics of thyroid nodules. National guidelines should be introduced].
|
Lakartidningen
|
2011
|
0.75
|
|
37
|
A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
|
Artif Organs
|
2007
|
0.75
|
|
38
|
Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.
|
Cancer
|
2010
|
0.75
|
|
39
|
Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
|
Clin Cancer Res
|
2005
|
0.75
|
|
40
|
[Fellowship success story in Lund].
|
Lakartidningen
|
2015
|
0.75
|
|
41
|
DNA ploidy, S-phase fraction and associations with 2-18F-fluoro-deoxy-2-D-glucose positron emission tomography findings before and during therapy of head and neck squamous cell carcinoma.
|
Acta Otolaryngol
|
2004
|
0.75
|
|
42
|
Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
|
Cancer
|
2002
|
0.75
|